Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET

In France, since the reimbursement of Lutathera®, this treatment is allowed for retreatment if patients still fulfill the criteria of its indication and 4 news cycles could be proposed. However, clinical practices are heterogeneous regarding the number of new cycles and most teams perform only two additional cycles (every 8 weeks). Therefore, the coordinator propose to evaluate the efficacy of two additional cycle of Lutathera® versus active surveillance in patients already retreated with two cycles Lutathera® for a new progression of intestinal neuroendocrine tumor and who previously received the 4 cycles of treatment with a clinical benefit.

NCT Number	NCT04954820
Lead Sponsor	Institut du Cancer de Montpellier - Val d'Aurelle
Conditions	Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor, Progressive Disease
Enrollment	146 participants
Start Date	2021-10-18
Primary Completion	2033-10 (estimated)
Study Completion	2033-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-04